Edition:
United States

DURECT Corp (DRRX.OQ)

DRRX.OQ on NASDAQ Stock Exchange Global Market

1.07USD
21 Sep 2018
Change (% chg)

$-0.03 (-2.73%)
Prev Close
$1.10
Open
$1.08
Day's High
$1.09
Day's Low
$1.03
Volume
543,153
Avg. Vol
143,883
52-wk High
$2.55
52-wk Low
$0.75

Chart for

About

Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY... (more)

Overall

Beta: 0.84
Market Cap(Mil.): $173.34
Shares Outstanding(Mil.): 162.00
Dividend: --
Yield (%): --

Financials

  DRRX.OQ Industry Sector
P/E (TTM): -- 108.33 32.69
EPS (TTM): -0.00 -- --
ROI: -2.92 1.50 12.72
ROE: -7.28 0.19 14.85

BRIEF-Durect Announces Amendment To Licensing Agreement With Sandoz

* DURECT ANNOUNCES AMENDMENT TO LICENSING AGREEMENT WITH SANDOZ RELATED TO POSIMIR® (SABER®-BUPIVACAINE)

May 09 2018

BRIEF-Durect Corporation Q1 Loss Per Share $0.05

* DURECT CORPORATION ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 02 2018

Earnings vs. Estimates